APGE

Apogee TherapeuticsC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+3

B+

Bull case

25%

Probability

Target price

$112.00

+42.3% vs current

Most likely

Base case

45%

Probability

Target price

$84.00

+6.7% vs current

B-

Bear case

30%

Probability

Target price

$62.00

-21.2% vs current

AI sentiment snapshot

Latest data as of 2026-05-14

AI commentary

Post-earnings sentiment is mixed rather than decisively positive. The official May 11, 2026 company release highlighted strong runway and multiple 2026 milestones, and checked secondary coverage showed an EPS beat versus consensus, but the stock reaction was soft: APGE closed at $84.60 on May 11, 2026, $82.22 on May 12, 2026, and the packet anchor was $83.94 on May 13, 2026. That pattern suggests good news was at least partly anticipated. Headline volume increased, but clear T+3 analyst target-reset evidence was not readily available from checked sources, so confidence should stay moderate.

RankAlpha Sentiment Codex - 2026-05-14

Open post-earnings memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-06-30eventAPEX Part B atopic dermatitis data due in Q2 2026High impact

Management said 16-week APEX Phase 2 Part B data for zumilokibart in AD are expected in Q2 2026 and will determine the induction regimen for planned Phase 3 trials, making this the next material de-risking event [#8-K-2026-05-11].

2026-10-31catalystAPG279 head-to-head interim data versus DUPIXENT in 2H 2026High impact

The company said the Phase 1b APG279 study versus DUPIXENT in AD is fully enrolled and expanded to 86 patients, with interim 24-week data expected in 2H 2026; positive combination data would broaden the upside case beyond monotherapy [#8-K-2026-05-11].

2026-11-30catalystPhase 3 AD start later in 2026High impact

Apogee said Phase 3 initiation in atopic dermatitis is expected in the second half of 2026, contingent on Part B dose selection and continued execution; this is the main path to sustaining the current premium clinical narrative [#8-K-2026-05-11].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-14 • Updated nightlySource: Internal modelMethodology